Another win for Pfizer as RSV vaccine receives FDA special status

US-based Pfizer has already received the FDA’s Breakthrough Therapy Designation for its RSV candidate for pregnant women, and has now been granted the same status in the indication for older patients.


As the battle to be first to the RSV market rages on, Pfizer brings home another win in New York.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs